Immunome

IMMUNOME INC

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Immunome Inc

Press Releases

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

General

ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment

OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Infinimmune Announces Research Collaboration with Immunome

ASPI

IMNM

INSM

KURA

RPTX

Ardelyx

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Immatics

MiMedx Group

Nanobiotix

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Precigen

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prime Medicine

Relay Therapeutics

Sana Biotechnology

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Tourmaline Bio

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Upstream Bio

Zenas BioPharma

Zymeworks

Goldman Sachs

Craig-Hallum

Guggenheim

Evercore ISI Group

JP Morgan

Comments

Immunome

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL